SAB BIOTHERAPEUTICS, INC. Tax Withholding Paid on Stock Awards
SAB BIOTHERAPEUTICS, INC. (SABS) reported Tax Withholding Paid on Stock Awards of $9.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $4.43K.
- SAB BIOTHERAPEUTICS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $4.57K, a 120.61% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $4.25K.
- SAB BIOTHERAPEUTICS, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $4.95K.
- SAB BIOTHERAPEUTICS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $11.21K, a 55.06% decline from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $24.93K.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month as first filed | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $4.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $9.00K 10-Q · filed 2026-08-06 | $13.25K derived: sum of 3 quarters · filed 2026-08-06 | $18.20K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $4.57K 10-Q · filed 2026-05-12 | $8.82K derived: sum of 2 quarters · filed 2026-05-12 | $13.78K derived: sum of 3 quarters · filed 2026-05-12 | $13.70K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $4.25K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $9.21K derived: sum of 2 quarters · filed 2026-03-09 | $9.13K derived: sum of 3 quarters · filed 2026-08-06 | $11.21K 10-K · filed 2026-03-09 | |
| 2025-09-30 | $4.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $4.88K derived: sum of 2 quarters · filed 2026-08-06 | $6.95K 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | -$72.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.00K 10-Q · filed 2026-08-06 | $2.07K 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | $2.07K 10-Q · filed 2026-05-12 | ||||
| 2024-12-31 | $24.93K 10-K · filed 2026-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |